Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures

Virology

Volumn 216, Issue 1, 1996, Pages 133-145

  Schoppel, K ^a   Hassfurther E ^a   Britt, W ^b   Ohlin, M ^c   Borrebaeck, C A K ^c   Mach, M ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b University of Alabama at Birmingham   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ANTIGEN BINDING; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE;

BACTERIA (MICROORGANISMS); CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; MURINAE;

EID: 0342961137     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1996.0040     Document Type: Article

References (63)

1. Adler, S. P., Starr, S. E., Plotkin, S. A., Hempfling, S. H., Buis, J., Manning, M. L., and Best, A. M. (1995). Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis. 171, 26-32.
2. Andreoni, M., Faircloth, M., Vugler, L., and Britt, W. J. (1989). A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J. Virol. Methods 23, 157-167.
3. Aulitzky, W. E., Schulz, T. F., Tilg, H., Niederwieser, D., Larcher, K., Ostberg, L., Scriba, M., Martindale, J., Stern, A. C., Grass, P., et al. (1991). Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: Report of a phase I trial in bone marrow transplant recipients. J. Infect. Dis. 163, 1344-1347.
4. Azuma, J., Kurimoto, T., Tsuji, S., Mochizuki, N., Fujinaga, S., Matsumoto, Y., and Masuho, Y. (1991). Phase I study on human monoclonal antibody against cytomegalovirus: Pharmacokinetics and immunogenicity. J. Immunother. 10, 278-285.
5. Baboonian, C., Blake, K., Booth, J. C., and Wiblin, C. N. (1989). Complement-independent neutralising monoclonal antibody with differential reactivity for strains of human cytomegalovirus. J. Med. Virol. 29, 139-145.
6. Beidler, C. B., Ludwig, J. R., Cardenas, J., Phelps, J., Papworth, C. G., Melcher, E., Sierzega, M., Myers, L. J., Unger, B. W., Fisher, M., et al. (1988). Cloning and high level expression of a chimeric antibody with specificity for human carcinoembryonic antigen. J. Immunol. 141, 4053-4060.
7. Britt, W. J. (1984). Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology 135, 369-378.
8. Britt, W. J., and Vugler, L. G. (1992). Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116). J. Virol. 66, 6747-6754.
9. Britt, W. J., Vugler, L., Butfiloski, E. J., and Stephens, E. B. (1990). Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 64, 1079-1085.
10. Bruggemann, M., Williams, G. T., Bindon, C. I., Clark, M. R., Walker, M. R., Jefferis, R., Waldmann, H., and Neuberger, M. S. (1987). Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166, 1351-1361.
11. Carroll, W. L., Mendel, E., and Levy, S. (1988). Hybridoma fusion cell lines contain an aberrant kappa transcript. Mol. Immunol. 25, 991-995.
12. Chehimi, J., Peppard, J., and Emanuel, D. (1987). Selection of an intravenous immune globulin for the immunoprophylaxis of cytomegalovirus infections: An in vitro comparison of currently available and previously effective immune globulins. Bone Marrow Transplant. 2, 395-402.
13. Chomczynski, P., and Sacchi, W. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159.
14. Chou, S. (1992). Comparative analysis of sequence variation in gp116 and gp55 components of glycoprotein B of human cytomegalovirus. Virology 188, 388-390.
15. Chou, S. W., and Dennison, K. M. (1991). Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J. Infect. Dis. 163, 1229-1234.
16. Cooper, L. J., Schimenti, J. C., Glass, D. D., and Greenspan, N. S. (1991). H chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate. J. Immunol. 146, 2659-2663.
17. Dangl, J. L., Wensel, T. G., Morrison, S. L., Stryer, L., Herzenberg, L. A., and Oi, V. T. (1988). Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J. 7, 1989-1994.
18. Darlington, J., Super, M., Patel, K., Grundy, J. E., Griffiths, P. D., and Emery, V. C. (1991). Use of the polymerase chain reaction to analyse sequence variation within a major neutralizing epitope of glycoprotein B (gp58) in clinical isolates of human cytomegalovirus. J. Gen. Virol. 72, 1985-1989.
19. Dimmock, N. (1987). Multiple mechanisms of neutralization of animal viruses. Trends Biochem. Sci. 12, 70-75.
20. Dulau, L., Cheyrou, A., Dubourdieu, D., and Aigle, M. (1989). Directed mutagenesis using PCR[published erratum appears in Nucleic Acids Res. 17, 3630, 1989]. Nucleic Acids Res. 17, 2873.
21. Fulpius, T., Spertini, F., Reininger, L., and Izui, S. (1993). Immunoglobulin heavy chain constant region determines the pathogenicity and the antigen-binding activity of rheumatoid factor. Proc. Natl. Acad. Sci. USA 90, 2345-2349.
22. Gonczol, E., deTaisne, C., Hirka, G., Berencsi, K., Lin, W. C., Paoletti, E., and Plotkin, S. (1991). High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: The importance of the gB protein in HCMV immunity. Vaccine 9, 631-637.
23. Gorman, S. D., and Clark, M. R. (1990). Humanisation of monoclonal antibodies for therapy. Semin. Immunol. 2, 457-466.
24. Greenspan, N. S., and Cooper, L. J. (1993). Cooperative binding by mouse IgG3 antibodies: Implications for functional affinity, effector function, and isotype restriction. Springer Semin. Immunopathol. 15, 275-291.
25. Grundy, J. E., Lui, S. F., Super, M., Berry, N. J., Sweny, P., Fernando, O. N., Moorhead, J., and Griffiths, P. D. (1988). Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus. Lancet 2, 132-135.
26. Grunow, R., Jahn, S., Porstmann, T., Kiessig, S. S., Steinkellner, H., Steindl, F., Mattanovich, D., Gurtler, L., Deinhardt, F., Katinger, H., et al. (1988). The high efficiency, human B cell immortalizing heteromyeloma CB-F7: Production of human monoclonal antibodies to human immunodeficiency virus. J. Immunol. Methods 106, 257-265.
27. Harlow, E., and Lane, D. (1988). "Antibodies. A Laboratory Manual." Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
28. Iorio, R. M., Syddall, R. J., Sheehan, J. P., Bratt, M. A., Glickman, R. L., and Riel, A. M. (1991). Neutralization map of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus: Domains recognized by monoclonal antibodies that prevent receptor recognition. J. Viol. 65, 4999-5006.
29. Jonjic, S., Pavic, I., Polic, B., Crnkovic, I., Lucin, P., and Koszinowski, U. H. (1994). Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179, 1713-1717.
30. Kabat, E., Wu, T. T., Perry, H., Gottesmann, K., and Foeller, C. (1991). Sequences of proteins of immunological interest. NIH Publication No. 91-3242.
31. Kniess, N., Mach, M., Fay, J., and Britt, W. J. (1991). Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J. Viol. 65, 138-146.
32. Lehner, R., Stamminger, T., and Mach, M. (1991). Comparative sequence analysis of human cytomegalovirus strains. J. Clin. Microbiol. 29, 2494-2502.
33. Marshall, G. S., Rabalais, G. P., Stout, G. G., and Waldeyer, S. L. (1992). Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J. Infect. Dis. 165, 381-384.
34. Meek, K. D., Hasemann, C. A., and Capra, J. D. (1989). Novel rearrangements at the immunoglobulin D locus. Inversions and fusions add to IgH somatic diversity. J. Exp. Med. 170, 39-57.
35. Morelock, M. M., Rothlein, R., Bright, S. M., Robinson, M. K., Graham, E. T., Sabo, J. P., Owens, R., King, D. J., Norris, S. H., Scher, D. S., et al. (1994). Isotype choice for chimeric antibodies affects binding properties. J. Biol. Chem. 269, 13048-13055.
36. Ohlin, M., Sundqvist, V. A., Mach, M., Wahren, B., and Borrebaeck, C. A. (1993). Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/ 116 (gB), as determined with human monoclonal antibodies. J. Virol. 67, 703-710.
37. Persson, M. A., Brown, S. E., Steward, M. W., Hammarstrom, L., Smith, C. I., Howard, C. R., Wahl, M., Rynnel Dagoo, B., Lefranc, G., and Carbonara, A. O. (1988). IgG subclass-associated affinity differences of specific antibodies in humans. J. Immunol. 140, 3875-3879.
38. Pfaff, E., Thiel, H. J., Beck, E., Strohmaier, K., and Schaller, H. (1988). Analysis of neutralizing epitopes on foot-and-mouth disease virus. J. Virol. 62, 2033-2040.
39. Plotkin, S. A. (1991). Cytomegalovirus vaccine development - past and present. Transplant. Proc. 23, 85-89.
40. Possee, R. D., Schild, G. C., and Dimmock, N. J. (1982). Studies on the mechanism of neutralization of influenza virus by antibody: Evidence that neutralizing antibody (anti-haemagglutinin) inactivates influenza virus in vivo by inhibiting virion transcriptase activity. J. Gen. Virol. 58, 373-386.
41. Rapp, M., Messerle, M., Lucin, P., and Koszinowski, U. H. (1993). "Multidisciplinary Approach to Understanding Cytomegalovirus Disease" (S. Michelson and S. A. Plotkin, Eds.), pp. 327-332. Excerpta Medica, Amsterdam.
42. Rasmussen, L. E., Nelson, R. M., Kelsall, D. C., and Merigan, T. C. (1984). Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc. Natl. Acad. Sci. USA 81, 876-880.
43. Roben, P., Moore, J. P., Thali, M., Sodroski, J., Barbas, C. F., and Burton, D. R. (1994). Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68, 4821-4828.
44. Roy, D. M., Grundy, J. E., and Emery, V. C. (1993). Sequence variation within neutralizing epitopes of the envelope glycoprotein B of human cytomegalovirus: Comparison of isolates from renal transplant recipients and AIDS patients. J. Gen. Virol. 74, 2499-2505.
45. Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., and Erlich, H. A. (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239, 487-491.
46. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). "Molecular Cloning. A Laboratory Manual." Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
47. Schmitz, H., and Essuman, S. (1986). Comparison of the neutralizing and ELISA antibody titres to human cytomegalovirus (HCMV) in human sera and in gamma globulin preparations. J. Med. Virol. 20, 177-182.
48. Simpson, J. A., Chow, J. C., Baker, J., Avdalovic, N., Yuan, S., Au, D., Co, M. S., Vasquez, M., Britt, W. J., and Coelingh, K. L. (1993). Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J. Virol. 67, 489-496.
49. Snydman, D. R. (1990). Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev. Infect. Dis. 12(Suppl. 7), S839-S848.
50. Spector, S. A., Hirata, K. K., and Newman, T. R. (1984). Identification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome. J. Infect. Dis. 150, 953-956.
51. Starr, S. E., Friedman, H. M., and Plotkin, S. A. (1991). The status of cytomegalovirus vaccine. Rev. Infect. Dis. 13(Suppl. 11), S964-S965.
52. Talbot, P., and Almeida, J. D. (1977). Human cytomegalovirus: Purification of enveloped virions and dense bodies. J. Gen. Virol. 36, 345-349.
53. Taylor, H. P., and Dimmock, N. J. (1985). Mechanisms of neutralization of influenza virus by IgM. J. Gen. Virol. 66, 903-907.
54. Taylor, H. P., Armstrong, S. J., and Dimmock, N. J. (1987). Quantitative relationships between an influenza virus and neutralizing antibody. Virology 159, 288-298.
55. Thali, M., Charles, M., Furman, C., Cavacini, L., Posner, M., Robinson, J., and Sodroski, J. (1994). Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J. Virol. 68, 674-680.
56. Urban, M., Britt, W., and Mach, M. (1992). The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J. Virol. 66, 1303-1311.
57. Urban, M., Winkler, T., Landini, M. P., Britt, W., and Mach, M. (1994). Epitope-specific distribution of IgG subclasses against antigenic domains on glycoproteins of human cytomegalovirus. J. Infect. Dis. 169, 83-90.
58. Utz, U., Britt, W., Vugler, L., and Mach, M. (1989). Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J. Virol. 63, 1995-2001.
59. van-Wyke-Coelingh, K., and Tierney, E. L. (1989). Antigenic and functional organization of human parainfluenza virus type 3 fusion glycoprotein. J. Virol. 63, 375-382.
60. Wagner, B., Kropff, B., Kalbacher, H., Britt, W., Sundqvist, V. A., Ostberg, L., and Mach, M. (1992). A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus. J. Virol. 66, 5290-5297.
61. Weissenhorn, W., Weiss, E., Schwirzke, M., Kaluza, B., and Weidle, U. H. (1991). Chimerization of antibodies by isolation of rearranged genomic variable regions by the polymerase chain reaction. Gene 106, 273-277.
62. Werner, B. G., Snydman, D. R., Freeman, R., Rohrer, R., Tilney, N. L., and Kirkman, R. L. (1993). Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: Analysis of usage under treatment IND status. The Treatment IND Study Group. Transplant. Proc. 25, 1441-1443.
63. Zaia, J. A. (1993). Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clin. Infect. Dis. 17(Suppl. 2), S392-S399.